These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9808805)

  • 1. Can computerized risk profiles help patients improve their coronary risk? The results of the Coronary Health Assessment Study (CHAS).
    Lowensteyn I; Joseph L; Levinton C; Abrahamowicz M; Steinert Y; Grover S
    Prev Med; 1998; 27(5 Pt 1):730-7. PubMed ID: 9808805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial.
    Grover SA; Lowensteyn I; Joseph L; Kaouache M; Marchand S; Coupal L; Boudreau G;
    Arch Intern Med; 2007 Nov; 167(21):2296-303. PubMed ID: 18039987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coaching patients On Achieving Cardiovascular Health (COACH): a multicenter randomized trial in patients with coronary heart disease.
    Vale MJ; Jelinek MV; Best JD; Dart AM; Grigg LE; Hare DL; Ho BP; Newman RW; McNeil JJ;
    Arch Intern Med; 2003 Dec 8-22; 163(22):2775-83. PubMed ID: 14662633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy.
    Bucher HC; Rickenbach M; Young J; Glass TR; Vallet Y; Bernasconi E; Cavassini M; Fux C; Schiffer V; Vernazza P; Weber R; Battegay M;
    Antivir Ther; 2010; 15(1):31-40. PubMed ID: 20167989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study.
    Jacobson TA; Gutkin SW; Harper CR
    Curr Med Res Opin; 2006 Jun; 22(6):1065-73. PubMed ID: 16846539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observed changes in the lipid profile and calculated coronary risk in patients given dietary advice in primary care.
    Price D; Ramachandran S; Knight T; Jones PW; Neary RH
    Br J Gen Pract; 2000 Sep; 50(458):712-5. PubMed ID: 11050787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recalculation of cardiovascular risk score as a surrogate marker of change in clinical care of diabetes patients: the Alphabet POEM project (Practice Of Evidence-based Medicine).
    Lee JD; Morrissey JR; Patel V;
    Curr Med Res Opin; 2004 May; 20(5):765-72. PubMed ID: 15140344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot trial of a computerized decision aid for breast cancer prevention.
    Ozanne EM; Annis C; Adduci K; Showstack J; Esserman L
    Breast J; 2007; 13(2):147-54. PubMed ID: 17319855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
    Clearfield MB; Weis SE; Willis JM; Vasenius KA; McConathy WJ
    J Am Osteopath Assoc; 2002 Jul; 102(7):377-84. PubMed ID: 12138952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apparent protective effect of high density lipoprotein against coronary heart disease in the elderly.
    Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
    Chin Med J (Engl); 2004 Apr; 117(4):511-5. PubMed ID: 15109440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
    Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
    Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients' ideas, fears and expectations of their coronary risk: barriers for primary prevention.
    van Steenkiste B; van der Weijden T; Timmermans D; Vaes J; Stoffers J; Grol R
    Patient Educ Couns; 2004 Nov; 55(2):301-7. PubMed ID: 15530768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque.
    Kowalski M
    J Physiol Pharmacol; 2001 Aug; 52(1 Suppl 1):3-31. PubMed ID: 11795863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of lipid lowering in patients with coronary artery disease by case method learning.
    Kiessling A; Zethraeus N; Henriksson P
    Int J Technol Assess Health Care; 2005; 21(2):180-6. PubMed ID: 15921057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.